Innogenetics buys HIV diagnostic range from AVANT:
This article was originally published in Clinica
Belgian company Innogenetics' North American subsidiary, based in Atlanta, Georgia, has bought AVANT Immunotherapeutics' TRAx product line for an undisclosed amount in cash and royalties. Innogenetics will have worldwide rights to sell, market and manufacture the line. The range includes the TRAx CD4, which is used to measure the number of CD4 cells in the blood of HIV sufferers to monitor disease progression and to determine treatment. The TRAx system is an enzyme-linked immunoassay that uses monoclonal antibodies for the measurement of specific T-lymphocytes in blood.